REFERENCES
1. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-1414.
2. Weller K, Groffik A, Church MK, et al. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol.2014;133(5):1365-1372, 1372.e1361-1366.
3. Weller K, Siebenhaar F, Hawro T, Altrichter S, Schoepke N, Maurer M. Clinical Measures of Chronic Urticaria. Immunol Allergy Clin North Am. 2017;37(1):35-49.
4. Park Y-M, Oh M-S, Kwon J-W. Predicting inadequate treatment response in children with chronic spontaneous urticaria. Pediatr Allergy Immunol. 2020;31(8):946-953.
5. Caffarelli C, Paravati F, El Hachem M, et al. Management of chronic urticaria in children: a clinical guideline. Ital J Pediatr.2019;45(1):101-101.
6. Maurer M, Giménez-Arnau A, Ensina LF, Chu C-Y, Jaumont X, Tassinari P. Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results. World Allergy Organ J.2020;13(9):100460-100460.
7. Lennox RD, Leahy MJ. Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life. Ann Allergy Asthma Immunol. 2004;93(2):142-146.
8. Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942-949.
9. Holme SA, Man I, Sharpe JL, Dykes PJ, Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality Index: validation of the cartoon version. Br J Dermatol. 2003;148(2):285-290.
10. Salek MS, Jung S, Brincat-Ruffini LA, et al. Clinical experience and psychometric properties of the Children’s Dermatology Life Quality Index (CDLQI), 1995-2012. Br J Dermatol. 2013;169(4):734-759.
11. Oztürkcan S, Ermertcan AT, Eser E, Sahin MT. Cross validation of the Turkish version of dermatology life quality index. Int J Dermatol. 2006;45(11):1300-1307.
12. Beattie* PE, Lewis-Jones MS. A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. Br J Dermatol. 2006;155(1):145-151.
13. Potter P, Mitha E, Barkai L, et al. Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2–11 years.Pediatr Allergy Immunol. 2016;27(1):55-61.
14. Weller K, Groffik A, Church MK, et al. Development and validation of the Urticaria Control Test: A patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol.2014;133(5):1365-1372.e1366.
15. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy.2021;n/a(n/a).
16. Miles LM, Gabrielli S, Le M, et al. Clinical Characteristics, Management, and Natural History of Chronic Inducible Urticaria in a Pediatric Cohort. Int Arch Allergy Immunol. 2021;182(8):757-764.
17. Kocatürk E, Kızıltaç U, Can P, et al. Validation of the Turkish version of the Urticaria Control Test: Correlation with other tools and comparison between spontaneous and inducible chronic urticaria.World Allergy Organ J. 2019;12(1):100009.
18. Bonett DG, Wright TA. Sample size requirements for estimating Pearson, Kendall and Spearman correlations. Psychometrika.2000;65(1):23-28.
19. Schober P, Boer C, Schwarte LA. Correlation Coefficients: Appropriate Use and Interpretation. Anesth Analg. 2018;126(5).
20. Waters A, Sandhu D, Beattie P, Ezughah F, Lewis-Jones S. Severity stratification of Children’s Dermatology Life Quality Index (CDLQI) scores: PA-8. Br J Dermatol. 2010;163.
21. Bruins FM, Bronckers IMGJ, Cai R, et al. Treatment persistence in paediatric and adolescent patients with psoriasis followed into young adulthood. From topical to systemic treatment: a prospective, longitudinal, observational cohort study of 448 patients*. Br J Dermatol. 2021;184(3):464-472.
22. Youden WJ. Index for rating diagnostic tests. Cancer.1950;3(1):32-35.
23. Hosmer DW, Lemeshow S, Sturdivant RX. Applied Logistic Regression. Wiley; 2013.
24. Finlay AY, Basra MKA. DLQI and CDLQI scores should not be combined.Br J Dermatol. 2012;167(2):453-454.
25. Itakura A, Tani Y, Kaneko N, Hide M. Impact of chronic urticaria on quality of life and work in Japan: Results of a real-world study.J Dermatol. 2018;45(8):963-970.
26. Kulthanan K, Chularojanamontri L, Tuchinda P, Rujitharanawong C, Maurer M, Weller K. Validity, reliability and interpretability of the Thai version of the urticaria control test (UCT). Health Qual Life Outcomes. 2016;14(1):61.
27. U. S. Department of Health Human Services, F. D. A. Center for Drug Evaluation Research, U. S. Department of Health Human Services, F. D. A. Center for Biologics Evaluation Research, U. S. Department of Health Human Services, F. D. A. Center for Devices Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance.Health Qual Life Outcomes. 2006;4(1):79.
28. Hawro T, Ohanyan T, Schoepke N, et al. The Urticaria Activity Score—Validity, Reliability, and Responsiveness. J Allergy Clin Immunol Pract. 2018;6(4):1185-1190.e1181.